by support | Nov 28, 2022 | Uncategorized
The FDA workshop on “The Development of Antibiotics for the Treatment of NTM Disease” on April 8, 2019 was very successful, with more than 100 people attending in person. The agenda focused on issues surrounding clinical trials and the development of a validated...
by support | Nov 28, 2022 | Uncategorized
Dear Friends of NTM Info & Research, It is with a mixture of gratitude and sadness that I announce the retirement of Philip Leitman as President of NTM Info & Research. Philip, who co-founded NTMir with his late wife, Fern, will continue as President Emeritus...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research (NTMir), the national nonprofit organization advocating on behalf of patients with nontuberculous mycobacterial (NTM) lung disease, applauds the European Commission’s decision to grant marketing authorization for ARIKAYCE® Liposomal 590 mg...
by support | Nov 28, 2022 | Uncategorized
Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter (CRL) from the FDA stating that they would not approve the treatment at this time. Many of you have communicated recently with the FDA...
by support | Nov 28, 2022 | Uncategorized
NTM Info & Research partnered with the National Organization for Rare Disorders (NORD) to help publish a Physician Guide to Nontuberculous Mycobacterial Lung Disease. The guide, which was authored by Dr. Leah Lande, is designed to help promote awareness of NTM...
